Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 References

Bortezomib/dexamethasone

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Bortezomib/dexamethasone is a combination drug against multiple myeloma.^[1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (orVel-DexorVeldex). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid.

References[edit]

^ Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, et al. (February 2010). "Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma". Leukemia & Lymphoma. 51 (2): 236–42. doi:10.3109/10428190903452826. PMID 20001242. S2CID 25932724.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.